Related Experiment Video

Updated: Dec 26, 2025

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.3K

The correlation between recurrent risk and CYP2C19 gene polymorphisms in patients with ischemic stroke treated with

Guohua Liu1, Sufang Yang1, Siqia Chen2

  • 1Department of Pharmacy.

Medicine
|March 17, 2020
PubMed

Insights

Patients with ischemic stroke (IS) taking clopidogrel have a higher risk of stroke recurrence if they are poor or intermediate metabolizers of the CYP2C19 gene. Carrying a CYP2C19 loss-of-function allele is an independent risk factor for recurrent stroke.

Area of Science:

  • Pharmacogenomics
  • Neurology
  • Cardiovascular Medicine

Background:

  • Clopidogrel is a common antiplatelet medication used for secondary prevention in patients with ischemic stroke (IS).
  • CYP2C19 gene polymorphisms can affect clopidogrel metabolism and efficacy.
  • Understanding the impact of these polymorphisms on stroke recurrence is crucial for optimizing patient treatment.

Purpose of the Study:

  • To investigate the association between CYP2C19 gene polymorphisms and the risk of recurrent stroke in IS patients treated with clopidogrel.
  • To identify specific CYP2C19 genotypes that confer a higher risk of stroke recurrence.

Main Methods:

  • A cohort of 289 IS patients regularly treated with clopidogrel was followed.
  • Stroke recurrence events were systematically recorded during the follow-up period.
  • Statistical analyses, including logistic regression, were performed to correlate CYP2C19 genotype with recurrence risk.

Main Results:

  • Among 289 patients, 41 experienced recurrent stroke within a 6-month follow-up.
  • Poor and intermediate CYP2C19 metabolizers showed a significantly higher risk of recurrent stroke compared to extensive metabolizers (ORs 2.88 and 3.00, respectively).
  • Carriers of the CYP2C19 *2 loss-of-function allele had a 3.30-fold increased risk of recurrence (P=.0065).

Conclusions:

  • CYP2C19 genotype significantly influences the risk of recurrent stroke in IS patients treated with clopidogrel.
  • Patients classified as poor or intermediate metabolizers, or carrying CYP2C19 loss-of-function alleles, require closer monitoring and potentially alternative treatment strategies.
  • Identifying these high-risk patients through genetic testing can aid in personalized secondary stroke prevention.
Abstract

More Related Videos

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease09:38

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

15.5K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.7K

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
970
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
186
Drug Product Performance: In Vitro–In Vivo Correlation01:20

Drug Product Performance: In Vitro–In Vivo Correlation

In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...
171
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
17.7K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
537
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
249